TATAA Biocenter is a Swedish life science company founded by Mikael Kubista. Kubista and other key personnel of TATAA Biocenter come from Chalmers University of Technology, which, like the company is located in Gothenburg. TATTA Biocenter is involved in molecular analysis, drug development and COVID-19 testing. [1] [2]
In 2021, Care Equity, controlled by investor Peter Batesko, invested in TATAA Biocenter. [1] To facilitate the investment, a new holding company, Bioholdings LP, was established to acquire TATAA. During restructuring connected to TATAA’s COVID-19 testing business, Kubista and his co-founders, advised by a law firm, Norma Advokater, carried out an upstream merger between two holding entities. This violated a clause in the agreement that prohibited share transfers without written consent. Peter Batesko, General Partner of Care Equity, refused to register the founders' ownership. In June 2023, Batesko dismissed Kubista as CEO and forfeited the founders' shares without compensation. [3] Peter Batesko and companies he controls then sued Kubista, the TATAA founders and their lawyer in what Kubista's lawyer has described as a SLAPP lawsuit. [4] Kubista also sued the law firm for negligent advice. [5]